Evidence map›Paper›PMID 20473774›Full record

ReviewAmino acids2012

Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities.

Ines Batinic-Haberle, Ivan Spasojevic, Hubert M Tse, Artak Tovmasyan, Zrinka Rajic, Daret K St Clair, Zeljko Vujaskovic, Mark W Dewhirst, Jon D Piganelli

Erratum issuedOpen access · bronzeAbstract readReview
In one paragraph

Review in Amino acids, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 113 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. HOxidative medicine and cellular longevity · 2021
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. MnTE-2-PyP Attenuates TGF-Oxidative medicine and cellular longevity · 2019
    Article
  16. Hematopoietic Stem Cells: Normal Versus Malignant.Antioxidants & redox signaling · 2018
    Review
  17. Review
  18. Review
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Ines Batinic-HaberleDepartment of Radiation Oncology, Duke University Medical Center, 281b/285 MSRB I, Durham, NC 27710, USA. ibatinic@duke.edu
Ivan Spasojevic
Hubert M Tse
Artak Tovmasyan
Zrinka Rajic
Daret K St Clair
Zeljko Vujaskovic
Mark W Dewhirst
Jon D Piganelli
Duke Medical Center · USChildren's Hospital of Pittsburgh · USDuke University · USUniversity of Alabama at Birmingham · USUniversity of Kentucky · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
Somatostatin analogues as countermeasures against intestinal radiation toxicityU19AI067798 · NIAID · DUKE UNIVERSITY · PI CHAO, NELSON J. · 2005 to 2024
$82.1M
Pilot Project for the DTMI CRA ProgramUL1RR024128 · NCRR · DUKE UNIVERSITY · PI CALIFF, ROBERT M · 2006 to 2010
$48.1M
TISSUEP01CA042745 · NCI · DUKE UNIVERSITY · PI JONES, ELLEN L · 1987 to 2009
$28.6M
Heat And Radiation Effects On Tumor MicrocirulationR01CA040355 · NCI · DUKE UNIVERSITY · PI DEWHIRST, MARK WESLEY · 1985 to 2013
$4.5M
Role of peroxynitrite in morphine hyperalgesia and toleranceR01DA024074 · NIDA · SAINT LOUIS UNIVERSITY · PI SALVEMINI, DANIELA · 2008 to 2012
$1.7M
MbSOD in chemotherapeutic-Induced Cardiac InjuryR01CA139843 · NCI · UNIVERSITY OF KENTUCKY · PI ST CLAIR, DARET K · 2008 to 2012
$1.3M
Mechanism of hypoxia mediated radiation lung injuryR01CA098452 · NCI · DUKE UNIVERSITY · PI VUJASKOVIC, ZELJKO · 2003 to 2006
$1.1M
NCI NIH HHS 5-P30-CA14236-29NCI NIH HHS CA 07359NCI NIH HHS CA 139843NCI NIH HHS CA40355-25NCI NIH HHS P01 CA042745NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA040355NCI NIH HHS R01 CA 098452NCI NIH HHS R01 CA098452NCI NIH HHS R01 CA139843NCRR NIH HHS 1 UL 1 RR024128-01NIAID NIH HHS U19 AI067798NIAID NIH HHS U19AI067798NIDA NIH HHS R01 DA024074
6 · The paper itself

Abstract

The most efficacious Mn(III) porphyrinic (MnPs) scavengers of reactive species have positive charges close to the Mn site, whereby they afford thermodynamic and electrostatic facilitation for the reaction with negatively charged species such as O (2) (•-) and ONOO(-). Those are Mn(III) meso tetrakis(N-alkylpyridinium-2-yl)porphyrins, more specifically MnTE-2-PyP(5+) (AEOL10113) and MnTnHex-2-PyP(5+) (where alkyls are ethyl and n-hexyl, respectively), and their imidazolium analog, MnTDE-2-ImP(5+) (AEOL10150, Mn(III) meso tetrakis(N,N'-diethylimidazolium-2-yl) porphyrin). The efficacy of MnPs in vivo is determined not only by the compound antioxidant potency, but also by its bioavailability. The former is greatly affected by the lipophilicity, size, structure, and overall shape of the compound. These porphyrins have the ability to both eliminate reactive oxygen species and impact the progression of oxidative stress-dependent signaling events. This will effectively lead to the regulation of redox-dependent transcription factors and the suppression of secondary inflammatory- and oxidative stress-mediated immune responses. We have reported on the inhibition of major transcription factors HIF-1α, AP-1, SP-1, and NF-κB by Mn porphyrins. While the prevailing mechanistic view of the suppression of transcription factors activation is via antioxidative action (presumably in cytosol), the pro-oxidative action of MnPs in suppressing NF-κB activation in nucleus has been substantiated. The magnitude of the effect is dependent upon the electrostatic (porphyrin charges) and thermodynamic factors (porphyrin redox ability). The pro-oxidative action of MnPs has been suggested to contribute at least in part to the in vitro anticancer action of MnTE-2-PyP(5+) in the presence of ascorbate, and in vivo when combined with chemotherapy of lymphoma. Given the remarkable therapeutic potential of metalloporphyrins, future studies are warranted to further our understanding of in vivo action/s of Mn porphyrins, particularly with respect to their subcellular distribution.

Indexed as

AnimalsHumansManganeseMetalloporphyrinsOxidation-ReductionOxidative StressTranscriptional ActivationManganeseMetalloporphyrins

Identifiers

PMID20473774
PMCPMC3022969
OpenAlexW1965431285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.